View Item 

Show simple item record

Radiotherapy in the management of glottic squamous cell carcinoma
dc.contributor.authorMendenhall, William M.
dc.contributor.authorStrojan, Primož
dc.contributor.authorLee, Anne W.M.
dc.contributor.authorRinaldo, Alessandra
dc.contributor.authorEisbruch, Avraham
dc.contributor.authorNg, Wai Tong
dc.contributor.authorSmee, Robert
dc.contributor.authorFerlito, Alfio
dc.date.accessioned2020-12-02T14:37:05Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-12-02T14:37:05Z
dc.date.issued2020-12
dc.identifier.citationMendenhall, William M.; Strojan, Primož ; Lee, Anne W.M.; Rinaldo, Alessandra; Eisbruch, Avraham; Ng, Wai Tong; Smee, Robert; Ferlito, Alfio (2020). "Radiotherapy in the management of glottic squamous cell carcinoma." Head & Neck 42(12): 3558-3567.
dc.identifier.issn1043-3074
dc.identifier.issn1097-0347
dc.identifier.urihttps://hdl.handle.net/2027.42/163562
dc.description.abstractIntroductionOur purpose is to review the role radiotherapy (RT) in the treatment of glottic squamous cell carcinoma (SCC).MethodsA concise review of the pertinent literature.ResultsRT cure rates are Tis- T1N0, 90% to 95%; T2N0, 70% to 80%; low- volume T3- T4a, 65% to 70%. Concomitant cisplatin is given for T3- T4a SCCs. Severe complications occur in 1% to 2% for Tis- T2N0 and 10% for T3- T4a SCCs. Patients with high- volume T3- T4 SCCs undergo total laryngectomy, neck dissection, and postoperative RT. Those with positive margins and/or extranodal extension receive concomitant cisplatin. The likelihood of local- regional control at 5- years is 85% to 90%. Severe complications occur in 5% to 10%.ConclusionsRT is a good treatment option for patients with Tis- T2N0 and low- volume T3- T4a glottic SCCs. Patients with higher volume T3- T4 cancers are best treated with surgery and postoperative RT.
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.otherextranodal extension
dc.subject.otherhead and neck
dc.subject.otherradiotherapy
dc.subject.othersquamous cell carcinoma
dc.subject.otherglottis
dc.titleRadiotherapy in the management of glottic squamous cell carcinoma
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163562/2/hed26419.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163562/1/hed26419_am.pdfen_US
dc.identifier.doi10.1002/hed.26419
dc.identifier.sourceHead & Neck
dc.identifier.citedreferenceForastiere AA, Ismaila N, Lewin JS, et al. Use of larynx- preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018; 36 ( 11 ): 1143 - 1169.
dc.identifier.citedreferenceCellai E, Frata P, Magrini SM, et al. Radical radiotherapy for early glottic cancer: results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1N0 disease. Int J Radiat Oncol Biol Phys. 2005; 63 ( 5 ): 1378 - 1386.
dc.identifier.citedreferenceFrata P, Cellai E, Magrini SM, et al. Radical radiotherapy for early glottic cancer: results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease. Int J Radiat Oncol Biol Phys. 2005; 63 ( 5 ): 1387 - 1394.
dc.identifier.citedreferenceWarde P, O’Sullivan B, Bristow RG, et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys. 1998; 41 ( 2 ): 347 - 353.
dc.identifier.citedreferenceLe QT, Fu KK, Kroll S, et al. Influence of fraction size, total dose, and overall time on local control of T1- T2 glottic carcinoma. Int J Radiat Oncol Biol Phys. 1997; 39 ( 1 ): 115 - 126.
dc.identifier.citedreferenceGarden AS, Forster K, Wong PF, Morrison WH, Schechter NR, Ang KK. Results of radiotherapy for T2N0 glottic carcinoma: does the - 2- stand for twice- daily treatment? Int J Radiat Oncol Biol Phys. 2003; 55 ( 2 ): 322 - 328.
dc.identifier.citedreferenceMendenhall WM, Amdur RJ, Hinerman RW, Villaret DB, Siemann DW. Postoperative radiation therapy for squamous cell carcinoma of the head and neck. Am J Otolaryngol. 2003; 24 ( 1 ): 41 - 50.
dc.identifier.citedreferenceDziegielewski PT, Reschly WJ, Morris CG, et al. Tumor volume as a predictor of survival in T3 glottic carcinoma: a novel approach to patient selection. Oral Oncol. 2018; 79: 47 - 54.
dc.identifier.citedreferenceWolf GT, Bellile E, Eisbruch A, et al. Survival rates using individualized bioselection treatment methods in patients with advanced laryngeal cancer. JAMA Otolaryngol Head Neck Surg. 2017; 143 ( 4 ): 355 - 366.
dc.identifier.citedreferenceWang X, Hu C, Eisbruch A. Organ- sparing radiation therapy for head and neck cancer. Nat Rev Clin Oncol. 2011; 8 ( 11 ): 639 - 648.
dc.identifier.citedreferenceCooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high- risk squamous- cell carcinoma of the head and neck. N Engl J Med. 2004; 350 ( 19 ): 1937 - 1944.
dc.identifier.citedreferenceNguyen- Tan PF, Zhang Q, Ang KK, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: long- term report of efficacy and toxicity. J Clin Oncol. 2014; 32 ( 34 ): 3858 - 3866.
dc.identifier.citedreferenceBeitler JJ, Zhang Q, Fu KK, et al. Final results of local- regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2014; 89 ( 1 ): 13 - 20.
dc.identifier.citedreferenceFeigenberg S, Patel K, Amdur RJ, Mendenhall WM. RTOG 9003: the untold story. Int J Radiat Oncol Biol Phys. 2014; 90 ( 2 ): 251 - 252.
dc.identifier.citedreferenceChang DT, Sandow PR, Morris CG, et al. Do pre- irradiation dental extractions reduce the risk of osteoradionecrosis of the mandible? Head Neck. 2007; 29 ( 6 ): 528 - 536.
dc.identifier.citedreferenceHarwood AR, Beale FA, Cummings BJ, Hawkins NV, Keane TJ, Rider WD. T3 glottic cancer: an analysis of dose time- volume factors. Int J Radiat Oncol Biol Phys. 1980; 6 ( 6 ): 675 - 680.
dc.identifier.citedreferenceWang CC. Carcinoma of the larynx. In: Wang CC, ed. Radiation Therapy for Head and Neck Neoplasms. 3rd ed. New York, NY: Wiley- Liss, Inc.; 1997: 221 - 255.
dc.identifier.citedreferenceStewart JG, Jackson AW. The steepness of the dose response curve both for tumor cure and normal tissue injury. Laryngoscope. 1975; 85 ( 7 ): 1107 - 1111.
dc.identifier.citedreferenceHarwood AR, Beale FA, Cummings BJ, Keane TJ, Payne D, Rider WD. T4NOMO glottic cancer: an analysis of dose- time volume factors. Int J Radiat Oncol Biol Phys. 1981; 7 ( 11 ): 1507 - 1512.
dc.identifier.citedreferenceKarim AB, Kralendonk JH, Njo KH, Tierie AH, Hasman A. Radiation therapy for advanced (T3T4N0- N3M0) laryngeal carcinoma: the need for a change of strategy: a radiotherapeutic viewpoint. Int J Radiat Oncol Biol Phys. 1987; 13 ( 11 ): 1625 - 1633.
dc.identifier.citedreferenceKnab BR, Salama JK, Solanki A, et al. Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Annal Oncol. 2008; 19 ( 9 ): 1650 - 1654.
dc.identifier.citedreferenceParsons JT, Mendenhall WM, Stringer SP, Cassisi NJ. T4 laryngeal carcinoma: radiotherapy alone with surgery reserved for salvage. Int J Radiat Oncol Biol Phys. 1998; 40 ( 3 ): 549 - 552.
dc.identifier.citedreferenceVengalil S, Giuliani ME, Huang SH, et al. Clinical outcomes in patients with T4 laryngeal cancer treated with primary radiotherapy versus primary laryngectomy. Head Neck. 2016; 38 ( suppl 1 ): E2035 - E2040.
dc.identifier.citedreferenceWick CC, Rezaee RP, Wang T, et al. Use of concurrent chemoradiation in advanced staged (T4) laryngeal cancer. Am J Otolaryngol. 2017; 38 ( 1 ): 72 - 76.
dc.identifier.citedreferenceWorden FP, Moyer J, Lee JS, et al. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope. 2009; 119 ( 8 ): 1510 - 1517.
dc.identifier.citedreferenceRosenthal DI, Mohamed AS, Weber RS, et al. Long- term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: a 3- decade survey. Cancer. 2015; 121 ( 10 ): 1608 - 1619.
dc.identifier.citedreferenceMendenhall WM, Morris CG, Stringer SP, et al. Voice rehabilitation after total laryngectomy and postoperative radiation therapy. J Clin Oncol. 2002; 20 ( 10 ): 2500 - 2505.
dc.identifier.citedreferenceMendenhall WM, Dagan R, Bryant CM, Amdur RJ, Mancuso AA. Definitive radiotherapy for squamous cell carcinoma of the glottic larynx. Cancer Control. 2016; 23 ( 3 ): 208 - 212.
dc.identifier.citedreferenceHinerman RW, Morris CG, Amdur RJ, et al. Surgery and postoperative radiotherapy for squamous cell carcinoma of the larynx and pharynx. Am J Clin Oncol. 2006; 29 ( 6 ): 613 - 621.
dc.identifier.citedreferenceHinerman RW, Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB. T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution’s 35- year experience. Am J Clin Oncol. 2007; 30 ( 2 ): 181 - 185.
dc.identifier.citedreferenceMendenhall WM, Mancuso AA, Hinerman RW, et al. Multidisciplinary management of laryngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007; 69 ( 2 suppl ): S12 - S14.
dc.identifier.citedreferenceSengupta N, Morris CG, Kirwan J, Amdur RJ, Mendenhall WM. Definitive radiotherapy for carcinoma in situ of the true vocal cords. Am J Clin Oncol. 2010; 33 ( 1 ): 94 - 95.
dc.identifier.citedreferenceChera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM. T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 78 ( 2 ): 461 - 466.
dc.identifier.citedreferenceMendenhall WM, Riggs CE, Vaysberg M, Amdur RJ, Werning JW. Altered fractionation and adjuvant chemotherapy for head and neck squamous cell carcinoma. Head Neck. 2010; 32 ( 7 ): 939 - 945.
dc.identifier.citedreferenceNewlin HE, Amdur RJ, Riggs CE, Morris CG, Kirwan JM, Mendenhall WM. Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. Cancer. 2010; 116 ( 19 ): 4533 - 4540.
dc.identifier.citedreferenceBernier J, Cooper JS. Chemoradiation after surgery for high- risk head and neck cancer patients: how strong is the evidence? Oncologist. 2005; 10 ( 3 ): 215 - 224.
dc.identifier.citedreferenceForastiere AA, Zhang Q, Weber RS, et al. Long- term results of RTOG 91- 11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013; 31 ( 7 ): 845 - 852.
dc.identifier.citedreferenceTrifiletti DM, Smith A, Mitra N, et al. Beyond positive margins and extracapsular extension: evaluating the utilization and clinical impact of postoperative chemoradiotherapy in resected locally advanced head and neck cancer. J Clin Oncol. 2017; 35 ( 14 ): 1550 - 1560.
dc.identifier.citedreferenceStrojan P, Haigentz M Jr, Bradford CR, et al. Chemoradiotherapy vs. total laryngectomy for primary treatment of advanced laryngeal squamous cell carcinoma. Oral Oncol. 2013; 49 ( 4 ): 283 - 286.
dc.identifier.citedreferenceAmerican Joint Committee on Cancer. AJCC Cancer Staging Handbook. 5th ed. Philadelphia, PA: Lippincott- Raven; 1997.
dc.identifier.citedreferenceAmerican Joint Committee on Cancer. AJCC Cancer Staging Handbook. 6th ed. New York, NY: Springer Verlag; 2002.
dc.identifier.citedreferenceDagan R, Morris CG, Bennett JA, et al. Prognostic significance of paraglottic space invasion in T2N0 glottic carcinoma. Am J Clin Oncol. 2007; 30 ( 2 ): 186 - 190.
dc.identifier.citedreferenceAaltonen LM, Rautiainen N, Sellman J, et al. Voice quality after treatment of early vocal cord cancer: a randomized trial comparing laser surgery with radiation therapy. Int J Radiat Oncol Biol Phys. 2014; 90 ( 2 ): 255 - 260.
dc.identifier.citedreferenceTiong A, Huang SH, O’Sullivan B, et al. Outcome following IMRT for T2 glottic cancer: the potential impact of image- guidance protocols on local control. J Radiat Oncol. 2014; 3 ( 3 ): 267 - 275.
dc.identifier.citedreferenceRock K, Huang SH, Tiong A, et al. Partial laryngeal IMRT for T2N0 glottic cancer: impact of image guidance and radiation therapy intensification. Int J Radiat Oncol Biol Phys. 2018; 102 ( 4 ): 941 - 949.
dc.identifier.citedreferenceMillion RR, Cassisi NJ, Mancuso AA. Larynx. In: Million RR, Cassisi NJ, eds. Management of Head and Neck: A Multidisciplinary Approach. 2nd ed. Philadelphia, PA: Lippioncott; 1994: 431 - 497.
dc.identifier.citedreferenceGregoire V, Evans M, Le QT, et al. Delineation of the primary tumour clinical target volumes (CTV- P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG- KHT, LPRHHT, NCIC CTG, NCRI, NRG oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018; 126 ( 1 ): 3 - 24.
dc.identifier.citedreferenceInternational Commission on Radiation Units and Measurements (ICRU). Prescribing, Recording, and Reporting Photon Beam Therapy. ICRU Report 50. Bethesda, MD: ICRU; 1993.
dc.identifier.citedreferenceChera BS, Amdur RJ, Morris CG, Mendenhall WM. Carotid- sparing intensity- modulated radiotherapy for early- stage squamous cell carcinoma of the true vocal cord. Int J Radiat Oncol Biol Phys. 2010; 77 ( 5 ): 1380 - 1385.
dc.identifier.citedreferenceCho EI, Sasaki CT, Haffty BG. Prognostic significance of pretreatment hemoglobin for local control and overall survival in T1- T2N0 larynx cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 58 ( 4 ): 1135 - 1140.
dc.identifier.citedreferenceWegner RE, Abel S, Bergin JJ, Colonias A. Intensity- modulated radiation therapy in early stage squamous cell carcinoma of the larynx: treatment trends and outcomes. Radiat Oncol J. 2020; 38 ( 1 ): 11 - 17.
dc.identifier.citedreferenceHong JC, Kruser TJ, Gondi V, et al. Risk of cerebrovascular events in elderly patients after radiation therapy versus surgery for early- stage glottic cancer. Int J Radiat Oncol Biol Phys. 2013; 87 ( 2 ): 290 - 296.
dc.identifier.citedreferenceOsman SO, Astreinidou E, de Boer HC, et al. IMRT for image- guided single vocal cord irradiation. Int J Radiat Oncol Biol Phys. 2012; 82 ( 2 ): 989 - 997.
dc.identifier.citedreferenceAl- Mamgani A, Kwa SL, Tans L, et al. Single vocal cord irradiation: image guided intensity modulated hypofractionated radiation therapy for T1a glottic cancer: early clinical results. Int J Radiat Oncol Biol Phys. 2015; 93 ( 2 ): 337 - 343.
dc.identifier.citedreferenceSpayne JA, Warde P, O’Sullivan B, et al. Carcinoma- in- situ of the glottic larynx: results of treatment with radiation therapy. Int J Radiat Oncol Biol Phys. 2001; 49 ( 5 ): 1235 - 1238.
dc.identifier.citedreferenceLe QT, Takamiya R, Shu HK, et al. Treatment results of carcinoma in situ of the glottis: an analysis of 82 cases. Arch Otolaryngol Head Neck Surg. 2000; 126 ( 11 ): 1305 - 1312.
dc.identifier.citedreferenceSmitt MC, Goffinet DR. Radiotherapy for carcinoma- in- situ of the glottic larynx. Int J Radiat Oncol Biol Phys. 1994; 28 ( 1 ): 251 - 255.
dc.identifier.citedreferenceKalter PO, Lubsen H, Delemarre JF, Snow GB. Squamous cell hyperplasia of the larynx (a clinical follow- up study). J Laryngol Otol. 1987; 101 ( 6 ): 579 - 588.
dc.identifier.citedreferencePene F, Fletcher GH. Results in irradiation of the in situ carcinomas of the vocal cords. Cancer. 1976; 37 ( 6 ): 2586 - 2590.
dc.identifier.citedreferenceSmee RI, Meagher NS, Williams JR, Broadley K, Bridger GP. Role of radiotherapy in early glottic carcinoma. Head Neck. 2010; 32 ( 7 ): 850 - 859.
dc.identifier.citedreferenceForner D, Rigby MH, Corsten M, Trites JR, Pyne J, Taylor SM. Oncological and functional outcomes after repeat transoral laser microsurgery for the treatment of recurrent early glottic cancer. J Laryngol Otol. 2020; 134 ( 2 ): 169 - 173.
dc.identifier.citedreferenceAmerican Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2018.
dc.identifier.citedreferenceOkumura M, Motegi A, Zenda S, et al. Efficacy and safety of accelerated fractionated radiotherapy without elective nodal irradiation for T3N0 glottic cancer without vocal cord fixation. Head Neck. 2020; 42: 1775 - 1782.
dc.identifier.citedreferenceYamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys. 2006; 64 ( 1 ): 77 - 82.
dc.identifier.citedreferenceDixon LM, Douglas CM, Shaukat SI, et al. Conventional fractionation should not be the standard of care for T2 glottic cancer. Radiat Oncol. 2017; 12 ( 1 ): 178.
dc.identifier.citedreferenceLyhne NM, Primdahl H, Kristensen CA, et al. The DAHANCA 6 randomized trial: effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma. Radiother Oncol. 2015; 117 ( 1 ): 91 - 98.
dc.identifier.citedreferenceRobert A, Pointreau Y, Janoray G, et al. A large French multicenter retrospective series of T1- T2N0 vocal cords carcinomas treated with exclusive irradiation. Cancer Radiother. 2017; 21 ( 4 ): 286 - 290.
dc.identifier.citedreferenceTrotti A 3rd, Zhang Q, Bentzen SM, et al. Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512). Int J Radiat Oncol Biol Phys. 2014; 89 ( 5 ): 958 - 963.
dc.identifier.citedreferenceBhateja P, Ward MC, Hunter GH, et al. Impaired vocal cord mobility in T2N0 glottic carcinoma: suboptimal local control with radiation alone. Head Neck. 2016; 38 ( 12 ): 1832 - 1836.
dc.identifier.citedreferenceSher DJ, Timmerman RD, Nedzi L, et al. Phase 1 fractional dose- escalation study of equipotent stereotactic radiation therapy regimens for early- stage glottic larynx cancer. Int J Radiat Oncol Biol Phys. 2019; 105 ( 1 ): 110 - 118.
dc.identifier.citedreferenceMendenhall WM, Holtzman AL, Dagan R, Bryant CM, Hitchock KE, Amdur RJ. In regard to Sher et al. Int J Radiat Oncol Biol Phys. 2020; 106 ( 1 ): 220 - 221.
dc.identifier.citedreferenceGroome PA, O’Sullivan B, Mackillop WJ, et al. Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: population- based outcomes study supporting need for intensified treatment schedules. Int J Radiat Oncol Biol Phys. 2006; 64 ( 4 ): 1002 - 1012.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hed26419_am.pdf
Size:
495.1KB
Format:
PDF
View/Open
Name:
hed26419.pdf
Size:
959.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.